These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35443373)

  • 1. Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
    Khaladkar K; Mohan B; Khaladkar K; Suryawanshi S; Barkatestrong/Strong H
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study.
    Sharma V; Chawla S; Garg S; Singh B
    Sultan Qaboos Univ Med J; 2024 May; 24(2):243-249. PubMed ID: 38828248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
    Dobbins R; Hussey EK; O'Connor-Semmes R; Andrews S; Tao W; Wilkison WO; Cheatham B; Sagar K; Hanmant B
    BMC Pharmacol Toxicol; 2021 Jun; 22(1):34. PubMed ID: 34120651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
    J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
    Dharmalingam M; Kumar Sharma S; Prakash V; Maiti A; Kumar R; Murthy LSS; Ramanathan B; Maheshwari S; Naik Kethavath S; Ogale D; Bachubhai PVK; Sonawane AB; Shah V; Suresh M; Chakraborty S; Kumar Manjunath K
    Cureus; 2024 Apr; 16(4):e58115. PubMed ID: 38738005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
    Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis.
    Ding Y; Liu Y; Qu Y; Lin M; Dong F; Li Y; Cao L; Lin S
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(8):2802-2817. PubMed ID: 35503625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
    Bolli G; Dotta F; Rochotte E; Cohen SE
    Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.